Postpartum drug lowers breast cancer risk

An international study has revealed that Cabergoline, a medication used to stop breast milk production after pregnancy loss or when breastfeeding is not possible, may reduce the risk of postpartum breast cancer by up to 70%. The findings indicate that the drug helps complete the involution process, which clears the breast of unnecessary tissue after weaning, and decreases the number of cells that could potentially become cancerous. Experiments on mice with mutations in the BRCA1 and TP53 genes showed about a fifty percent reduction in tumor development, suggesting its potential role in prevention—especially for mothers at higher risk. However, the necessary clinical trials to confirm these findings are still underway.